Demographics and HR in propensity score matched analysis
| N | SEC versus ETN | ADA versus ETN | IFX versus ETN | GOL versus ETN | CER versus ETN | |||||
| 251:251 | 826:826 | 745:745 | 473:473 | 240:240 | ||||||
| Line, mean (SD) | 2.7 (1.0) | 2.7 (1.0) | 1.6 (1.0) | 1.6 (1.0) | 1.5 (1.1) | 1.5 (1.0) | 1.7 (1.0) | 1.6 (0.9) | 2.0 (1.0) | 2.0 (1.0) |
| Age, mean (SD) | 47 (13) | 46 (13) | 44 (13) | 45 (13) | 43 (14) | 43 (14) | 42 (14) | 42 (13) | 43 (14) | 42 (12) |
| Sex, n (%) men | 111 (44) | 104 (41) | 446 (54) | 447 (54) | 401 (54) | 393 (53) | 274 (58) | 283 (60) | 109 (45) | 110 (46) |
| AU ever*, n (%) | 47 (19) | 52 (21) | 217 (26) | 211 (26) | 138 (19) | 150 (20) | 119 (25) | 128 (27) | 54 (23) | 58 (24) |
| AU 1 year 2, n (%) | 19 (8) | 20 (8) | 79 (10) | 74 (9) | 59 (8) | 58 (8) | 48 (12) | 55 (10) | 24 (10) | 24 (10) |
| Patient global assessment, mean (SD) | 65 (22) | 59 (24) | 55 (24) | 58 (23) | 58 (24) | 59 (23) | 54 (25) | 57 (21) | 59 (24) | 58 (23) |
| BASDAI, mean (SD) | 6.2 (2.1) | 5.5 (2.1) | 5.3 (2.2) | 5.5 (2.1) | 5.6 (2.0) | 5.5 (2.0) | 5.1 (2.3) | 5.4 (1.9) | 5.8 (2.2) | 5.7 (2.1) |
| AU events‡ | 18 | 20 | 55 | 79 | 35 | 60 | 42 | 42 | 19 | 19 |
| HR AU-diagnosis | 1.56 (0.80–3.05) | Ref | 0.56 (0.40–0.78) | Ref | 0.50 (0.34–0.73) | Ref | 0.55 (0.36–0.85) | Ref | 0.80 (0.39–1.67) | Ref |
| HR AU-diagnosis Adjusted§ | 1.59 (0.79–3.18) | Ref | 0.55 (0.39–0.78) | Ref | 0.50 (0.34–0.73) | Ref | 0.53 (0.34–0.81) | Ref | 0.79 (0.38–1.64) | Ref |
The propensity scores were based on, age, sex, line of treatment and prior AU history, see the Methods section.
*Any registration of AU prior to treatment start.
†Any registration of AU in year prior to treatment start.
‡Number of patients with an event (=first AU-diagnosis) during follow-up.
§Adjusted for patient global assessment.
ADA, adalimumab; AU, anterior uveitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CER, certolizumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; SEC, secukinumab.